<DOC>
	<DOCNO>NCT00149643</DOCNO>
	<brief_summary>Adolescents diagnose major depressive disorder often also diagnose marijuana dependence . Fluoxetine antidepressant medication currently use treat young people diagnose major depressive disorder . The purpose study determine effectiveness fluoxetine treat adolescent young adult diagnose major depressive disorder marijuana dependence .</brief_summary>
	<brief_title>Effectiveness Fluoxetine Young People Treatment Major Depression Marijuana Dependence</brief_title>
	<detailed_description>Marijuana dependence common illicit substance use disorder United States . Its prevalence high among adolescent young adult . Major depressive disorder one common condition see marijuana dependent individual . Fluoxetine antidepressant medication treatment major depression among adolescent child . The purpose study determine effectiveness fluoxetine treat adolescent young people dually diagnose major depressive disorder marijuana dependence . Participants 12-week trial randomly assign receive either fluoxetine placebo . Participants initially randomly assign receive either 10 mg fluoxetine placebo . Medication give morning . If side effect observe first two week study , medication increase daily dose 20 mg fluoxetine placebo . If , Week 4 , participant continue demonstrate significant depressive symptom , medication increase 30 mg daily . All participant also receive Treatment Usual ( TAU ) acute phase trial , consist motivation enhancement therapy ( MET ) Cognitive Behavioral Therapy ( CBT ) . Outcome measure obtain screening , baseline , weekly interval first four week treatment phase ; obtain biweekly final 8 week treatment phase . Blood drawn baseline Weeks 4 , 8 , 12 ass level three liver enzyme ( Gamma-glutamyl Transferase ( gGTP ) , Aspartate aminotransferase ( SGOT ) , Alanine aminotransferase ( SGPT ) ) . This provide biochemical monitoring drink behavior medication compliance . The 12-week acute phase study supplement 9-month naturalistic follow-up phase , care transfer study provider community provider . The study end 1-year follow-up evaluation .</detailed_description>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Marijuana Abuse</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<criteria>DSMIV diagnosis current marijuana abuse dependence , confirm SCIDSUD DSMIV diagnosis current major depressive disorder , confirm KSADS Marijuana use least two day within week prior enrollment Demonstrated adequate level depressive symptom within week prior enrollment DSMIV diagnosis bipolar disorder , schizoaffective disorder , schizophrenia Hypo hyperthyroidism Significant cardiac , neurological , kidney impairment Liver disease ( SGOT , SGPT , gammaGTP great 3 time normal level ) Use antipsychotic antidepressant medication month prior enrollment DSMIV dependence substance except marijuana nicotine ; alcohol dependence , history drug use History significant medication side effect SSRI antidepressant Pregnant Unable use adequate contraceptive method duration study Inability read understand English</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Cannabis</keyword>
	<keyword>MDD</keyword>
</DOC>